Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CareDx, Inc.CDNA · Entity 4344 | Director | July 07, 2025 | July 10, 2025 |
| Kyverna Therapeutics, Inc.KYTX · Entity 5452 | Director · Chief Executive Officer | February 07, 2024 | February 08, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CareDx, Inc.
Report date July 07, 2025 · Filed July 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 308,846 |
Reported balance
After 2025-07-07 transaction · row 1
1 source rowRow 1 · 2025-07-07 · Sale · Disposed 10,000 · Balance 308,846 F1: The transaction reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the Reporting Person on August 21, 2024. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.40 to $18.86 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the Reporting Person on August 21, 2024.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.40 to $18.86 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Kyverna Therapeutics, Inc.
Report date February 07, 2024 · Filed February 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,220 |
Reported balance
Holding disclosure · report date 2024-02-07 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 58,220 |
| Common StockSEC Table I · non-derivative | IndirectBy The Maag Family Irrevocable Trust | 349,321 |
Reported balance
Holding disclosure · report date 2024-02-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 349,321 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.83 · Expires 2033-11-05 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-02-07 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F1: 25% of the original number of shares subject to the option shall vest on January 1, 2025, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.33 · Expires 2033-07-12 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-02-07 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F2: 25% of the original number of shares subject to the option shall vest on July 1, 2024, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.15 · Expires 2032-11-21 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-02-07 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F3: 25% of the original number of shares subject to the option vested on October 13, 2023, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the original number of shares subject to the option shall vest on January 1, 2025, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
F2: 25% of the original number of shares subject to the option shall vest on July 1, 2024, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
F3: 25% of the original number of shares subject to the option vested on October 13, 2023, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Miromatrix Medical Inc.
Report date December 12, 2023 · Filed December 13, 2023
Section 16 reporting ended · disclosed 2023-12-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,368 |
Reported balance
After 2023-12-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-12-12 · Other · Disposed 62,092 · Balance 58,368 F1: Shares tendered and accepted pursuant to the terms of an offer conducted pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, United Therapeutics Corporation ("Parent") and Morpheus Subsidiary Inc., dated as of October 29, 2023, for consideration consisting of (i) $3.25 per share, payable in cash, without interest and less any required withholding taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"). F2: Each CVR entitles the reporting person to potentially receive contingent payments of up to an aggregate of $1.75 per CVR, without interest and less any required withholding taxes, upon the achievement of a specified milestone in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement"), dated as of December 12, 2023, by and between Parent and Continental Stock Transfer & Trust Company. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-12-13 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-12-13 · Disposition to issuer · Disposed 58,368 · Balance 0 F3: Previously unvested restricted stock units ("RSUs"), each of which represented a contingent right to receive one share of the Issuer's common stock. F4: In connection with the closing under the Merger Agreement, each outstanding RSU award was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to the RSU award multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such RSU award. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares tendered and accepted pursuant to the terms of an offer conducted pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, United Therapeutics Corporation ("Parent") and Morpheus Subsidiary Inc., dated as of October 29, 2023, for consideration consisting of (i) $3.25 per share, payable in cash, without interest and less any required withholding taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR").
F2: Each CVR entitles the reporting person to potentially receive contingent payments of up to an aggregate of $1.75 per CVR, without interest and less any required withholding taxes, upon the achievement of a specified milestone in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement"), dated as of December 12, 2023, by and between Parent and Continental Stock Transfer & Trust Company.
F3: Previously unvested restricted stock units ("RSUs"), each of which represented a contingent right to receive one share of the Issuer's common stock.
F4: In connection with the closing under the Merger Agreement, each outstanding RSU award was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to the RSU award multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such RSU award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 13, 2018 Filed Nov 16, 2018 02:55 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 50,000 | $26.48 | $1,323,945.00 |
DisclosureSEC source: 0000899243-18-029076 · doc4.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 389,747 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 22, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.47 to $28.25, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares sold at each separate price. Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 01:25 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 15,000 | $23.10 | $346,542.00 |
DisclosureSEC source: 0000899243-18-023781 · doc4.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 439,747 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.4 to $23.49, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares sold at each separate price. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 21:36 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $12.24 | $0.00 |
DisclosureSEC source: 0000899243-18-019279 · doc4.xml · derivative · entry 5 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-06-29 F4 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on June 1, 2019 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 21:36 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-019279 · doc4.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,037 F2 · shares: The reported securities are represented by restricted stock units, 100% of which were vested upon grant. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 21:36 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-019279 · doc4.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,037 F1 · shares: The reported securities are represented by restricted stock units, 1/4th of which shall vest on June 1, 2019 and 1/4th of which shall vest on each anniversary thereafter. Read SEC document |
| June 29, 2018 Filed Jul 12, 2018 23:17 UTC Amendment | CareDx, Inc. CDNA · Entity 4344 | Tax withholdingCommon Stock | 17,290 | $12.24 | $211,629.60 |
DisclosureSEC source: 0000899243-18-019823 · doc4a.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 454,747 F1 · kind: This amendment is being filed solely to report the withholding of shares by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of vested restricted stock units. Read SEC document |
| March 27, 2018 Filed Mar 28, 2018 20:46 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 15,000 | $7.87 | $118,035.00 |
DisclosureSEC source: 0000899243-18-008719 · doc4.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,037 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.63 to $8.01, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares sold at each separate price. Read SEC document |
| March 20, 2018 Filed Mar 21, 2018 22:00 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0000899243-18-008270 · doc4.xml · derivative · entry 4 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2022-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 2/48ths of the shares subject to this option vested and became exercisable on the Date Exercisable set forth in column 6 and each month thereafter until October 1, 2013. 1/36th of the remaining shares vested and became exercisable each month thereafter. Read SEC document |
| March 20, 2018 Filed Mar 21, 2018 22:00 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 50,000 | $0.55 | $27,400.00 |
DisclosureSEC source: 0000899243-18-008270 · doc4.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 02:37 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionStock Option (Right to Buy) · Derivative | 89,938 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0000899243-18-004365 · doc4.xml · derivative · entry 4 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 89,938 shares Expires 2022-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 2/48ths of the shares subject to this option vested and became exercisable on the Date Exercisable set forth in column 6 and each month thereafter until October 1, 2013. 1/36th of the remaining shares vested and became exercisable each month thereafter. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 02:37 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 89,938 | $0.55 | $49,286.02 |
DisclosureSEC source: 0000899243-18-004365 · doc4.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2018 Filed Jan 30, 2018 21:55 UTC | CareDx, Inc. CDNA · Entity 4344 | Tax withholdingCommon Stock | 1,450 | $6.25 | $9,062.50 |
DisclosureSEC source: 0000899243-18-002269 · doc4.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,099 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain restricted stock units. Read SEC document |
| January 22, 2018 Filed Jan 23, 2018 23:47 UTC | CareDx, Inc. CDNA · Entity 4344 | Tax withholdingCommon Stock | 3,726 | $6.29 | $23,436.54 |
DisclosureSEC source: 0000899243-18-001704 · doc4.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,124 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain restricted stock units. Read SEC document |
| January 22, 2018 Filed Jan 26, 2018 00:45 UTC Amendment | CareDx, Inc. CDNA · Entity 4344 | Tax withholdingCommon Stock | 3,726 | $6.29 | $23,436.54 |
DisclosureSEC source: 0000899243-18-002028 · doc4a.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,549 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain restricted stock units. F2 · balance_after: This amendment is being filed solely to correct the number of non-derivative securities reported on the original Form 4 as beneficially owned by the Reporting Person as of January 22, 2018; 44,425 shares of the Issuer's common stock were inadvertently omitted. Read SEC document |
| January 19, 2018 Filed Jan 26, 2018 00:32 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantEmployee Stock Option (right to buy) · Derivative | 44,425 | $0.00 Strike: $6.31 | $0.00 |
DisclosureSEC source: 0000899243-18-002010 · doc4.xml · derivative · entry 4 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,425 Underlying: Common Stock · 44,425 shares Expires 2028-01-19 F3 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on January 19, 2019 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| January 19, 2018 Filed Jan 26, 2018 00:32 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 44,425 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002010 · doc4.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,275 F1 · shares: The reported securities are represented by restricted stock units 1/4th of which shall vest on January 19, 2019 and 1/4th of which shall vest on each anniversary thereafter. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 21:08 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantOption to Purchase Common Stock · Derivative | 69,474 | Not disclosed Strike: $5.49 | Not disclosed |
DisclosureSEC source: 0000899243-17-026015 · doc4.xml · derivative · entry 2 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,474 Underlying: Common Stock · 69,474 shares Expires 2024-11-09 F3 · security: Represents a stock option granted pursuant to the Exchange Offer (the "New Options"). F4 · derivative.exercise_price: The exercise price per share equals the closing price per share of the Company's common stock, as quoted by NASDAQ, on November 9, 2017. F2 · price: On November 8, 2017, pursuant to the offer by CareDx, Inc. (the "Company") to exchange certain outstanding stock options for new options as more fully described in the Schedule TO-I, filed with the Securities Exchange Commission on October 12, 2017, as amended and supplemented on October 24, 2017 and November 9, 2017(the "Exchange Offer"), the Company cancelled a stock option for 113,868 shares granted to the reporting person on April 8, 2014. In exchange for such cancelled stock option, the reporting person received a stock option for 69,474 shares. F5 · derivative.exercise_date: The New Options are scheduled to vest in three equal installments based upon the Company's achievement of certain performance goals as follows: (i) one third of the New Options vest upon the Company's determination, which has been reviewed by the Company's independent registered public accounting firm, that the Company has achieved $10 million of total cumulative sales of Allosure, its proprietary next-generation sequencing-based test to detect donor-derived, cell-free DNA after transplantation, commencing after the completion of the Exchange Offer, (ii) one third of the New Options vest upon the Company's determination, which has been reviewed by the Company's independent registered public accounting firm, that the Company has achieved quarterly revenues of at least $18.75 million for two consecutive fiscal quarters commencing after the completion of the Exchange Offer, F6 · derivative.exercise_date: (Continued from Footnote 5) and (iii) one third of the New Options vest in the event the closing sales price of the Company's common stock is at or above $5.00 per share, as quoted by NASDAQ, for 10 consecutive trading days after the completion of the Exchange Offer. Read SEC document |
| November 08, 2017 Filed Nov 13, 2017 21:08 UTC | CareDx, Inc. CDNA · Entity 4344 | Disposition to issuerOption to Purchase Common Stock · Derivative | 113,868 | Not disclosed Strike: $12.40 | Not disclosed |
DisclosureSEC source: 0000899243-17-026015 · doc4.xml · derivative · entry 1 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 113,868 shares Expires 2024-04-08 F2 · price: On November 8, 2017, pursuant to the offer by CareDx, Inc. (the "Company") to exchange certain outstanding stock options for new options as more fully described in the Schedule TO-I, filed with the Securities Exchange Commission on October 12, 2017, as amended and supplemented on October 24, 2017 and November 9, 2017(the "Exchange Offer"), the Company cancelled a stock option for 113,868 shares granted to the reporting person on April 8, 2014. In exchange for such cancelled stock option, the reporting person received a stock option for 69,474 shares. F1 · derivative.exercise_date: 102,006 of the shares underlying the cancelled option were vested and immediately exercisable. The remaining shares underlying the cancelled option were scheduled to vest monthly in increments of 1/48th of the shares subject to the options. Read SEC document |
| October 27, 2017 Filed Oct 30, 2017 21:56 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantEmployee Stock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0000899243-17-024890 · doc4.xml · derivative · entry 1 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2027-10-27 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on October 20, 2018 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 22:27 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantEmployee Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0000899243-17-021468 · doc4.xml · derivative · entry 1 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-09-01 F1 · derivative.exercise_date: 50% of the shares subject to the option shall vest on September 1, 2018 and 1/72nd of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| August 15, 2017 Filed Aug 16, 2017 22:22 UTC | CareDx, Inc. CDNA · Entity 4344 | PurchaseCommon Stock | 350 | $1.82 | $637.00 |
DisclosureSEC source: 0000899243-17-020531 · doc4.xml · nonDerivative · entry 3 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,850 Read SEC document |
| August 15, 2017 Filed Aug 16, 2017 22:22 UTC | CareDx, Inc. CDNA · Entity 4344 | PurchaseCommon Stock | 150 | $1.82 | $272.99 |
DisclosureSEC source: 0000899243-17-020531 · doc4.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,500 Read SEC document |
| August 15, 2017 Filed Aug 16, 2017 22:22 UTC | CareDx, Inc. CDNA · Entity 4344 | PurchaseCommon Stock | 100 | $1.81 | $181.00 |
DisclosureSEC source: 0000899243-17-020531 · doc4.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,350 Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 23:39 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantEmployee Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0000899243-17-005011 · doc4.xml · derivative · entry 4 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2027-02-17 F5 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on January 27, 2018 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 23:39 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-005011 · doc4.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,250 F1 · shares: The reported securities are represented by restricted stock units 1/4th of which shall vest on January 27, 2018 and 1/4th of which shall vest on each yearly anniversary thereafter. F2 · balance_after: Includes 6,000 shares that Reporting Person acquired pursuant to Issuer's 2014 Employee Stock Purchasing Plan; 3,000 shares on June 30, 2015 and 3,000 shares on June 30, 2016. Read SEC document |
| September 26, 2016 Filed Oct 4, 2016 20:58 UTC | CareDx, Inc. CDNA · Entity 4344 | PurchaseCommon Stock | 10,000 | $4.00 | $40,000.00 |
DisclosureSEC source: 0000899243-16-030860 · doc4.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,250 F1 · balance_after: Includes 3,000 shares that Reporting Person acquired pursuant to Issuer's 2014 Employee Stock Purchase Plan on July 1, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.